Related references
Note: Only part of the references are listed.Response to Biologics During the First Six Months of Therapy in Biologic-naive Patients with Psoriasis Predicts Risk of Disease Flares: A Danish Nationwide Study
Nikolai Loft et al.
ACTA DERMATO-VENEREOLOGICA (2021)
Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review
Kelly A. Reynolds et al.
EXPERT OPINION ON DRUG SAFETY (2020)
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry
Bente Glintborg et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study
Nikolai Dyrberg Loft et al.
ACTA DERMATO-VENEREOLOGICA (2019)
Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis
N. D. Loft et al.
PHARMACOGENOMICS JOURNAL (2018)
Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab
Jeanette Halskou Hesselvig et al.
ACTA DERMATO-VENEREOLOGICA (2018)
Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis
A. Egeberg et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes
Hillel P. Cohen et al.
DRUGS (2018)
Genetic polymorphisms associated with psoriasis and development of psoriatic arthritis in patients with psoriasis
Nikolai Dyrberg Loft et al.
PLOS ONE (2018)
Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
Lars Erik Kristensen et al.
BIODRUGS (2018)
Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars
Andras Inotai et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Treatment history of patients receiving biologic therapy for psoriasis - a Danish nationwide study
N. Loft et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
Robert Moots et al.
CURRENT RHEUMATOLOGY REPORTS (2017)
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
Bente Glintborg et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Drug Survival Studies in Dermatology: Principles, Purposes, and Pitfalls
Juul M. P. A. van den Reek et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Richard B. Warren et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort
O. Ahlehoff et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Pharmacological Undertreatment of Coronary Risk Factors in Patients with Psoriasis: Observational Study of the Danish Nationwide Registries
Ole Ahlehoff et al.
PLOS ONE (2012)
Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris
R. Gniadecki et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies
Erik von Elm et al.
PLOS MEDICINE (2007)
Share Paper
